Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] The company is engaged in providing healthcare services with renal insufficiency treatment. It marked inconsistency in its net earnings for the reported periods and the sudden surge in bottom in for 9M-FY24 raise eyebrows and concern over its sustainability going forward. Based on its super annualized FY24 earnings, the issue appears aggressively priced. There is no harm in skipping this pricey bet. Read detail review...
Nephro Care India Limited peer comparison with similar listed entities. (As on March 31, 2023)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Nephro Care India Limited | 1.94 | 1.94 | 2.44 | 55.15 | 79.68 | 36.89 |
Nephro Care IPO Reviews, analysis and views by popular members. Read Nephro Care India Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
RHP